Supernus Pharmaceuticals Financial Ratios
NASDAQ: SUPNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
42.67+0.53 (+1.26%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Supernus Pharmaceuticals ratio analysis
Supernus Pharmaceuticals earned a net margin of -5.4% in FY 2025, down from 11.2% a year earlier. Gross margin was 89.6% compared with a median of 89.9% over the prior 9 years. Return on equity reached -3.6%, meaning Supernus Pharmaceuticals generated -0.04 dollars of profit for every dollar of shareholders' equity.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Supernus Pharmaceuticals financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | — | 27.97 | 1,447.00 | 34.30 | 29.76 | 10.66 | 11.24 | 16.75 | 36.90 | 14.35 |
| Price / sales | 3.88 | 3.07 | 2.60 | 2.87 | 2.67 | 2.54 | 3.15 | 4.37 | 6.69 | 5.81 |
| Price / book | 2.63 | 1.96 | 1.71 | 2.16 | 1.90 | 1.78 | 2.08 | 3.94 | 7.56 | 6.51 |
| Gross margin | 89.6% | 88.2% | 86.2% | 86.9% | 87.1% | 89.9% | 95.8% | 96.2% | 95.0% | 94.4% |
| Operating margin | -8.7% | 12.3% | -0.9% | 6.9% | 14.8% | 33.4% | 37.8% | 35.3% | 32.9% | 25.2% |
| Net margin | -5.4% | 11.2% | 0.2% | 9.1% | 9.2% | 24.4% | 28.8% | 27.1% | 19.0% | 42.4% |
| Free cash flow margin | 6.4% | 25.9% | 18.2% | 17.4% | 21.9% | 25.9% | 35.7% | 31.3% | 37.3% | 30.3% |
| Return on equity (ROE) | -3.6% | 7.1% | 0.1% | 6.9% | 6.5% | 17.0% | 19.0% | 24.5% | 21.4% | 47.6% |
| Return on assets (ROA) | -2.7% | 5.4% | 0.1% | 3.6% | 3.2% | 8.4% | 9.7% | 11.4% | 13.5% | 29.5% |
| Debt / equity | — | — | — | — | 0.46 | — | — | — | — | — |
| Current ratio | 1.90 | 2.35 | 1.70 | 1.07 | 1.91 | 2.57 | 2.94 | 3.06 | 1.86 | 1.88 |
| Revenue growth | 8.6% | 8.9% | -8.9% | 15.1% | 11.4% | 32.5% | -3.9% | 35.3% | 40.6% | 45.8% |
| EPS growth | -151.5% | 6,500.0% | -98.1% | 6.1% | -58.5% | 12.4% | 2.4% | 89.8% | -38.6% | 528.6% |